Jump to contents

Researcher Information

last modified:2022/04/08

Associate Professor ASAKURA Hidesaku

Mail Laboratory Website
Laboratory Website

Faculty, Affiliation

University Hospital

College and School Educational Field

Division of Medical Sciences, Graduate School of Medical Science
Division of Medicine, Graduate School of Medical Science
School of Medicine, College of Medical, Pharmaceutical and Health Sciences
School of Pharmacy, College of Medical, Pharmaceutical and Health Sciences


 TEL:076-265-2275 FAX:076-234-4252

Academic Background

【Academic background(Doctoral/Master's Degree)】
Kanazawa University Doctor Graduate School, Division of Medicine 1987
【Academic background(Bachelor's Degree)】
Kanazawa University 1984


Kanazawa University School of Medicine Department of Internal Medicine(1984-)
Kanazawa University School of Medicine Department of Internal Medicine(1987-1995)
Kanazawa University School of Medicine Department of Internal Medicine(1995-1998)
Kanazawa University Hospital(1998-2014)
Kanazawa University Hospital(2014-)

Year & Month of Birth

Academic Society









Hematology、Laboratory medicine、Emergency medicine

Speciality Keywords

Coagulopathy, Laboratory medicine, DIC, Antiphospholipid syndrome, Thrombosis, Bleeding

Research Themes

Pathophysiology and treatment in disseminated intravascular coagulation

Pathophysiology in antiphospholipid antibody syndrome



COVID-19 associated coagulopathy



  •  Therapeutic strategies for disseminated intravascular coagulation associated with aortic aneurysm. Yamada S, Asakura H Int J Mol Sci 23 3 1296 2022
  •  Potential of continuous tPA infusion for multiple-organ failure from lipopolysaccharide-induced disseminated intravascular coagulation in rats. Suga Y, Tashiro K, Staub Y, Komura S, Yamada S, Morishita E, Asakura H Thromb Res 206 84-87 2021
  •  Coagulopathy and fibrinolytic pathophysiology in COVID-19 and SARS-CoV-2 vaccination Yamada S, Asakura H Int J Mol Sci 23 6 3338 2022
  •  Overcoming bleeding events related to extracorporeal membrane oxygenation in COVID-19 Asakura H, Ogawa H Lancet Respir Med 8 12 e87-8 2020
  •  COVID-19 associated coagulopathy and disseminated intravascular coagulation. Asakura H, Ogawa H Int J Hematol  113 45-57 2021/01

show all

  •  Potential of heparin and nafamostat combination therapy for COVID-19. Asakura H, Ogawa H J Thromb Haemost 18 1521-1522 2020
  •  Diversity of disseminated intravascular coagulation and selection of appropriate treatments. Asakura H Int J Hematol  113 10-14 2021/01
  •  Blue Rubber Bleb Nevus Syndrome Complicated by Enhanced-Fibrinolytic-Type DIC Yamada S, Arahata M, Morishita E, Asakura H Ann Vasc Dis 14 252-255 2021
  •  Recombinant human erythropoietin attenuates hepatic dysfunction by suppressing the hepatocellular Apoptosis in lipopolysaccharide-induced disseminated intravascular coagulation in rats. Suga Y, Akita F, Yamada S, Morishita E, Asakura H Biomed Rep 16 1 5 2022
  •  Effect of NOS inhibitors and anticoagulants on nitric oxide production in a tissue-factor induced rat DIC model. Suga Y, Takahashi Y, Shimada T, Yamada S, Morishita E, Asakura H In Vivo 35 1999-2004 2021
  •  Vaccine-induced immune thrombotic thrombocytopenia (VITT) - update on diagnosis and management considering different resources: COMMENT from Yamada et al. Yamada S, Asakura H J Thromb Haemost 20 540-541 2022
  •  Possibility of PMX-DHP therapy as a principal strategy against cytokine storm in COVID-19 - Insights from reconstructed coagulation data. Ogawa H, Kakuchi Y, Asakura H J Clin Apher 36 785-786 2021
  •  Etiology and management of bleeding during ECMO in a COVID-19 patient. Yamada S, Ogawa H, Asakura H J Atheroscler Thromb 28 402-403 2021
  •  Detailed exploration of pathophysiology involving inflammatory status and bleeding symptoms between lipopolysaccharide- and tissue factor-induced disseminated intravascular coagulation in rats.  Suga Y, Kubo A, Katsura H, Staub Y, Tashiro K, Yamada Y, Morishita E, Asakura H Int J Hematol 114 172-178 2021
  •  Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation. Takahashi W, Yoneda T, Koba H, Ueda T, Tsuji N, Ogawa H, Asakura H Int J Infect Dis 102 529-531 2021
  •  Consideration of Tranexamic Acid Administration to COVID-19 Patients. Ogawa H, Asakura H (Co-first author) 100 1595-1596 2020
  •  Management of disseminated intravascular coagulation associated with aortic aneurysm and vascular malformations Yamada S, Asakura H Int J Hematol 113 15-23 2021/01
  •  All-trans retinoic acid is partially effective against lipopolysaccharide-induced but not against tissue-factor-induced DIC in rat models Blood Coagul Fibrinolysis 12 4 301-306 2001/06
  •  An enhanced fibrinolysis prevents the development of multiple organ failure in disseminated intravascular coagulation in spite of much activation of blood coagulation Crit Care Med 29 6 164-1168 2001/06
  •  Beneficial Effect of the Active Form of Vitamin D3 against LPS-Induced DIC but not against Tissue-Factor-Induced DIC in Rat Models THROMBOSIS AND HAEMOSTASIS 85 2 287-290 2001/02
  •  CD20-positive T-cell chronic lymphocytic leukaemia Br J Haematol 102 5 1327-1329 1998/09
  •  Coagulative and fibrinolytic activation in cerebrospinal fluid and plasma after subarachnoid hemorrhage NEUROSURGERY 41 2 344-349 1997/08
  •  Decreased Plasma Activity of Antithrombin or Protein C is not Due to Consumption Coagulopathy in Septic Patients with DIC Eur J Haematol 67 3 170-175 2001/09
  •  Depressed plasma activity of plasminogen or a2 plasmin inhibitor is not due to consumption coagulopathy in septic patients with DIC Blood Coagul Fibrinolysis 12 4 275-281 2001/06
  •  Effect of losartan, an angiotensin II receptor antagonist, on the fibrinilytic system in hypertensive patients Int J Heamatol 70 1 60-61 1999/07
  •  Elevated levels of free tissue factor pathway inhibitor antigen in cases of disseminated intravascular coagulation caused by various underlying diseases Blood Coagul Fibrinolysis 12 1 1-8 2001/01
  •  Elevated plasma levels of free-form of TFPI antigen in hypercholesterolemic patients ATHEROSCLEROSIS 154 1 203-212 2001/01
  •  Increased plasma levels of free tissue factor pathway inhibitor in patients with Graves' disease Thromb Haemost 79 5 919-923 1998/05
  •  Marked difference in pathophysiology between tissue factor- and lipopolysaccharide-induced disseminated intravascular coagulation models in rats CRITICAL CARE MEDICINE 30 1 161-164 2002/01
  •  Menatetrenone, a vitamin K2 analog, ameliorates cytopenia in patients with refractory anemia of myelodysplastic syndrome Ann Hematol 81 1 16-19 2002/01
  •  One missense mutation in the factor X gene causing factor X deficiency (factor X Kanazawa) Int J Heamatol 73 3 390-392 2001/04
  •  Pneumonitis and eosinophilia induced by ethambutol J Allergy Clin Immunol 100 5 712-713 1997/11
  •  Prednisolone inhibits endotoxin-induced disseminated intravascular coagulation and improves mortality in rats: importance of inflammatory cytokine suppression Blood Coagul Fibrinolysis 10 6 321-330 1999/09
  •  Prevalence of deep vein thrombosis in the lower limbs and the pelvis and pulmonary embolism in patients with positive antiphospholipid antibodies ANNALS OF NUCLEAR MEDICINE 15 6 495-497 2001/12
  •  Prothrombin Fragment 1+2 Measures Treatment Effect in Patients with Antiphospholipid Syndrome THROMBOSIS RESEARCH 91 3 121-128 1998/08
  •  Short-term effects of fluvastatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor, on coagulation and the fibrinolytic system in patients with hypercholesterolemia Int J Heamatol 69 4 274-276 1999/06
  •  Treatment of disseminated intravascular coagulation(DIC) with all-trans retinoic acid in an endotoxin-induced rat model SEMINARS IN THROMBOSIS AND HEMOSTASIS 24 3 227-231 1998
  •  Vitamin K administration to elderly patients with osteoporosis induces no hemostatic activation, even in those with suspected vitamin K deficiency OSTEOPOROSIS INTERNATIONAL 12 12 996-1000 2001/12
  •  Induction of vasoactive substances differs in LPS-induced and TF-induced DIC models in rats THROMBOSIS AND HAEMOSTASIS 88 663-667 2002
  •  Antithrombotic role of nitric oxide in rats under physiological conditions THROMBOSIS AND HAEMOSTASIS 91 71-75 2004
  •  Role of fibrinolysis in tissue-factor-induced disseminated intravascular coagulation in rats---an effect of tranexamic acid HAEMATOLOGICA 89 757-758 2004
  •  Beneficial effect of low-molecular-weight heparin against LPS-induced DIC in rats is abolished by co-administration of tranexamic acid INTENSIVE CARE MEDICINE 30 1950-1955 2004
  •  Selective inducible nitric oxide synthase inhibition attenuates organ dysfunction and elevated endothelin levels in LPS-induced DIC model rats 3 1050-1055 2005
  •  Beneficial effects of urokinase on lipopolysaccharide-induced DIC in rats - focus on organ function and endothelin levels THROMBOSIS AND HAEMOSTASIS 93 724-728 2005
  •  Immunoglobulin preparations attenuate organ dysfunction and hemostatic abnormality by suppressing the production of cytokines in lipopolysaccharide-induced DIC in rats. CRITICAL CARE MEDICINE 34 9 2421-2425 2006
  •  Evaluation of hemostatic molecular markers for disseminated intravascular coagulation in patients with infections THROMBOSIS AND HAEMOSTASIS 95 2 282-287 2006
  •  No interplay between the pathways mediating coagulation and inflammation in tissue factor-induced DIC in rats CRITICAL CARE MEDICINE 34 10 2646-2650 2006
  •  The effect of combined therapy of danaparoid sodium and tranexamic acid on chronic disseminated intravascular coagulation associated with abdominal aortic aneuysm Circ J 69 9 1150-1153 2005
  •  Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of phase III randomized, double-blind, clinical trial J Thromb Haemost 5 1 31-41 2007
  •  High incidence of cytomegalovirus reactivation in adult recipients of an unrelated cord blood transplant HAEMATOLOGICA 90 9 1290-1292 2005
  •  Primary tracheal lymphoma: case report and literature review INTERNATIONAL JOURNAL OF HEMATOLOGY 82 4 338-342 2005
  •  Treatment of primary central nervous system lymphoma with induvtion of complement-dependent cytotoxicity by intraventicular administration of autologous-serum-supplemented rituximab Cancer Sci 97 1 80-83 2006
  •  Prospective trial of high-dose chemotherapy followed by infusions of peripheral blood stem cells and dose-escalated donor lymphocytes for relapsed leukemia after allogeneic stem cell transplantation INTERNATIONAL JOURNAL OF HEMATOLOGY 82 5 449-455 2005
  •  Effects of sarpogrelate hydrochloride in a patient with chronic graft-versus-host disease: a case report AMERICAN JOURNAL OF HEMATOLOGY 81 2 121-123 2006
  •  Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease INTERNATIONAL JOURNAL OF HEMATOLOGY 83 1 80-85 2006
  •  Successful treatment of minimal residual disease-positive Philadelphia chromosome-positive acute lymphoblastic leukemia with imatinib followed by reduced-intensity unrelated cord blood transplantation after allogeneic peripheral blood stem cell transplantation INTERNATIONAL JOURNAL OF HEMATOLOGY 84 2 170-173 2006
  •  Reduced-intensity unrelated cord blood transplantation for treatment of metastatic renal cell carcinoma: first evidence of cord-blood-versus-solid-tumor effect BONE MARROW TRANSPLANTATION 38 11 729-732 2006
  •  Safety and efficacy of foscarnet for preemptive therapy against cytomegalovirus reactivation after unrelated cord blood transplamtation TRANSPLANTATION PROCEEDINGS 39 1 237-239 2007
  •  Two case reports of inherited antithrombin deficiency: a novel frameshift mutation and a large deletion including all seven exons detected using two methods Sekiya, Akiko;Morishita, Eriko;Karato, Megumi;Maruyama, Keiko;Shimogawara, Itsumi;Omote, Mika;Wakugawa, Yoshiyuki;Shinohara, Moeko;Hayashi, Tomoe;Kadohira, Yasuko;Asakura, Hidesaku;Nakao, Shinji;Ohtake, Shigeki INTERNATIONAL JOURNAL OF HEMATOLOGY 93 2 216-219 2011
  •  Plasma Levels of Platelet-Derived Microparticles in Patients with Obstructive Sleep Apnea Syndrome Maruyama, Keiko;Morishita, Eriko;Sekiya, Akiko;Omote, Mika;Kadono, Tadaaki;Asakura, Hidesaku;Hashimoto, Masami;Kobayashi, Masako;Nakatsumi, Yasuto;Takada, Shigeo;Ohtake, Shigeki JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS 19 1 98-104 2012
  •  MASSIVE AMOUNTS OF TISSUE FACTOR INDUCE FIBRINOGENOLYSIS WITHOUT TISSUE HYPOPERFUSION IN RATS Hayakawa, Mineji;Gando, Satoshi;Ieko, Masahiro;Honma, Yoshinori;Homma, Taeko;Yanagida, Yuichiro;Kubota, Nobuhiko;Uegaki, Shinji;Sawamura, Atsushi;Asakura, Hidesaku SHOCK 39 6 514-519 2013 
  •  Antithrombin deficiency in three Japanese families: One novel and two reported point mutations in the antithrombin gene Maruyama, Keiko;Morishita, Eriko;Karato, Megumi;Kadono, Tadaaki;Sekiya, Akiko;Goto, Yukie;Sato, Tomomi;Nomoto, Haruka;Omi, Wataru;Tsuzura, Sachie;Imai, Hidenori;Asakura, Hidesaku;Ohtake, Shigeki;Nakao, Shinji THROMBOSIS RESEARCH 132 2 E118-E123 2013 
  •  Plasma levels of platelet-derived microparticles in patients with obstructive sleep apnea syndrome Maruyama, Keiko; Morishita, Eriko; Sekiya, Akiko; Omote, Mika; Kadono, Tadaaki; Asakura, Hidesaku; Hashimoto, Masami; Kobayashi, Masako; Nakatsumi, Yasuto; Takada, Shigeo; Ohtake, Shigeki Journal of Atherosclerosis and Thrombosis 19 1 98-104 2012/02/09 
  •  Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: A secondary survey Iba, Toshiaki; Saitoh, Daizoh; Wada, Hideo; Asakura, Hidesaku Critical Care 18 5 2014/09/15 
  •  Coagulation and fibrinolysis abnormalities in familial amyloid polyneuropathy Takahashi, Ryoichi; Ono, Kenjiro; Ikeda, Tokuhei; Akagi, Akio; Noto, Daisuke; Nozaki, Ichiro; Sakai, Kenji; Asakura, Hidesaku; Iwasa, Kazuo; Yamada, Masahito Amyloid 19 3 129-132 2012/09/01 
  •  Carbon monoxide (CO)-releasing molecule-derived CO regulates tissue factor and plasminogen activator inhibitor type 1 in human endothelial cells Maruyama, Keiko; Morishita, Eriko; Yuno, Takeo; Sekiya, Akiko; Asakura, Hidesaku; Ohtake, Shigeki; Yachie, Akihiro Thrombosis Research 130 3 e188-e193 2012/09/01 
  •  Antithrombin deficiency in three Japanese families: One novel and two reported point mutations in the antithrombin gene Maruyama, Keiko; Morishita, Eriko; Karato, Megumi; Kadono, Tadaaki; Sekiya, Akiko; Goto, Yukie; Sato, Tomomi; Nomoto, Haruka; Omi, Wataru; Tsuzura, Sachie; Imai, Hidenori; Asakura, Hidesaku; Ohtake, Shigeki; Nakao, Shinji Thrombosis Research 132 2 e118-e123 2013/08/01 
  •  A case of acquired FXIII deficiency with severe bleeding symptoms Hayashi, Tomoe; Kadohira, Yasuko; Morishita, Eriko; Asakura, Hidesaku; Souri, Masayoshi; Ichinose, Akitada Haemophilia 18 4 618-620 2012/07/01 
  •  Complete hemostasis achieved by factor XIII concentrate administration in a patient with bleeding after teeth extraction as a complication of aplastic anemia and chronic disseminated intravascular coagulation.  Yamada S, Okumura H, Morishita E, Asakura H Blood Coagul Fibrinolysis 31 274-278 2020
  •  Molecular genetic analysis of inherited protein C deficiency caused by the novel large deletion across two exons of PROC. Togashi T, Meguro-Horike M, Nagaya S, Sugihara S, Ichinohe T, Araiso Y, Yamaguchi K, Mori K, Imai Y, Kuzasa K, Horike SI, Asakura H, Watanabe A, Morishita E Thromb Res 188 115-118 2020
  •  Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study.  Yasaka M, Yokota H, Suzuki M, Asakura H, Yamane T, Ogi Y, Ochiai K, Nakayama D Cardiol Ther 9 167-188 2020
  •  Etiology and management of bleeding during ECMO in a COVID-19 patient.  Yamada S, Ogawa H, Asakura H J Atheroscler Thromb 2021/01
  •  Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation. Takahashi W, Yoneda T, Koba H, Ueda T, Tsuji N, Ogawa H, Asakura H Int J Infect Dis 102 529-531 2021/01
  •  The adjunctive therapies for early withdrawal from extracorporeal membrane oxygenation. Ogawa H, Asakura H J Card Surg  35 3671–3672 2020
  •  Perspective on fibrinolytic therapy in COVID-19: The potential of inhalation therapy against suppressed-fibrinolytic-type DIC. Asakura H, Ogawa H J Intensive Care 8 71 2020

Conference Presentations


Arts and Fieldwork


Theme to the desired joint research

○Disseminated intravascular coagulation, DIC
○pathophysiology of thrombosis and hemostasis

Grant-in-Aid for Scientific Research

○「D I Cにおける病型別の炎症と凝固の相互作用と血管作動性物質の意義」(2019-2021) 
○「D I Cにおける炎症と凝固の相互作用と血管作動性物質の制御」(2022-2024) 

Competitive research funding,Contribution

Collaborative research,Consignment study

Classes (Bachelors)

○Clinical Chemistry(2021)
○Clinical Chemistry(2020)
○Immunology & Allergic Disorders(2019)
○Clinical Chemistry(2019)
○Clinical Chemistry(2018)
○Immunology & Allergic Disorders(2018)

Classes (Graduate Schools)

International Project

International Students

Lecture themes

Others (Social Activities)

To Page Top